


(51) International Patent Classification:
C07K 16/28 (2006.01)(21) International Application Number:
PCT/US2019/039757(22) International Filing Date:
28 June 2019 (28.06.2019)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/691,913 29 June 2018 (29.06.2018) US(71) Applicant: **ALECTOR LLC** [US/US]; 131 Oyster Point
Blvd, Suite 600, South San Francisco, California 94080
(US).(72) Inventors: **PINCETIC, Andrew**; c/o Alector LLC, 131
Oyster Point Blvd, Suite 600, South San Francisco, Cali-
fornia 94080 (US). **CULP, Patricia**; c/o Alector LLC, 131
Oyster Point Blvd, Suite 600, South San Francisco, Califor-
nia 94080 (US). **ROSENTHAL, Arnon**; c/o Alector LLC,
131 Oyster Point Blvd, Suite 600, South San Francisco, Cal-
ifornia 94080 (US).(74) Agent: **SCARR, PHD, Rebecca B.**, et al.; McNeill Baur
PLLC, 500 W. Silver Spring Drive, Suite K-200, Glendale,
Wisconsin 53217 (US).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(54) Title: ANTI-SIRP-BETA1 ANTIBODIES AND METHODS OF USE THEREOF

(57) Abstract: The present disclosure is generally directed to compositions that include antibodies, *e.g.*, monoclonal, antibodies, anti-
body fragments, *etc.*, that specifically bind a SIRPβ1 polypeptide, *e.g.*, a human SIRPβ1, and use of such compositions in preventing,
reducing risk, or treating an individual in need thereof.

[Continued on next page]

Published:

- *without international search report and to be republished
upon receipt of that report (Rule 48.2(g))*
- *with sequence listing part of description (Rule 5.2(a))*